Company / Cash & Equivalents
CG Oncology, Inc. Cash & Equivalents History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$32.5M
FY2025
5-year range
$8.3M / $257.1M
FY2023-FY2025
Trend
-87.4%
vs FY2024
Sector context
#195 of 206
Health Care
What the data says
Among 206 Health Care companies, CG Oncology, Inc. is in the bottom 5% for cash & equivalents. Improved from $8M to $32M over the past 2 years.
Based on SEC 10-K filings.
$32M in FY2025.
Improved from $8M to $32M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 206This company $32.5M Sector average $672.3M
▼
-95.2% below sector average
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 87.4% year-over-year.
- Ranks #195 out of 206 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 8.02 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $32.5M | -87.4% |
| FY2024 | $257.1M | +3009.9% |
| FY2023 | $8.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026